Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
MOUNTAIN VIEW, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 at 8:30 a.m. PST. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.
A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. A replay of the webcast will be available on the Company's website for two weeks following the live presentation.
About ChemoCentryx
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. CCX168, a C5aR inhibitor, is in Phase II development for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). CCX168 appears to be safe, well tolerated and successful in allowing reduction and elimination of high-dose steroids, part of standard of care for AAV patients, without compromising efficacy or safety during a 12-week treatment period. CCX168 is also in Phase II studies for the treatment of atypical hemolytic uremic syndrome (aHUS) and immunoglobulin A nephropathy, or IgA nephropathy (IgAN). CCX872, a CCR2 inhibitor, successfully completed Phase I development and is in development for the treatment of non-resectable pancreatic cancer. CCX140, a distinct CCR2 inhibitor, successfully completed a Phase II clinical trial where it was shown to be safe and well tolerated while demonstrating statistically significant improvement in albuminuria in patients with diabetic nephropathy. Other clinical programs include CCX507, a next generation CCR9 inhibitor, which has successfully completed Phase I development, vercirnon (also known as Traficet-EN or CCX282) a specific CCR9 inhibitor for the treatment of inflammatory bowel disease, and CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in advanced preclinical development.
Source: ChemoCentryx, Inc.
CCXI-G
Contacts: Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer [email protected] Media: Denise Powell 510.703.9491 [email protected] Investors: Kimberly Minarovich Burns McClellan 212.213.0006 [email protected]
